Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes

Back

ESC Premium Access

Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes

Session: Clinical questions: management of patients with atrial fibrillation

Topic: Prevalence and Incidence of Atrial Fibrillation

Speaker: Associate Professor Y. Kim (Gwangju, KR)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Associate Professor Yoo Ri Kim

Chonnam National University Hospital, Gwangju (Korea (Republic of))

3 presentations

0 follower

4 more presentations in this session

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation: A nationwide cohort study

Speaker: Doctor T. Chao (Taipei, TW)

Oral anticoagulation in atrial fibrillation patients at intermediate risk of stroke: a nationwide registry-based cohort (Atrial Fibrillation in Norway - AFNOR)

Speaker: Doctor M. Anjum (Baerum, NO)

Are the results of the RATE-AF trial reproducible in daily practice? Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation

Speaker: Professor L. Fauchier (Tours, FR)

Low incidence of major complications after the first six hours post-atrial fibrillation ablation - same-day discharge safe and feasible in most patients

Speaker: Doctor A. Paul Nordin (Stockholm, SE)

Access the full session

Clinical questions: management of patients with atrial fibrillation

Speakers: Associate Professor Y. Kim, Doctor T. Chao, Doctor M. Anjum, Professor L. Fauchier, Doctor A. Paul Nordin

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources